Roncador, Giovanna;
Punet-Ortiz, Joan;
Maestre, Lorena;
Rodriguez-Lobato, Luis Gerardo;
Jimenez, Scherezade;
Reyes-Garcia, Ana Isabel;
Garcia-Gonzalez, Alvaro;
... Engel, Pablo; + view all
(2022)
CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma.
Cancers
, 14
(9)
, Article 2154. 10.3390/cancers14092154.
Preview |
Text
CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma.pdf - Accepted Version Download (4MB) | Preview |
Abstract
CD229 (Ly9) homophilic receptor, which belongs to the SLAM family of cell-surface molecules, is predominantly expressed on B and T cells. It acts as a signaling molecule, regulating lymphocyte homoeostasis and activation. Studies of CD229 function indicate that this receptor functions as a regulator of the development of marginal-zone B cells and other innate-like T and B lymphocytes. The expression on leukemias and lymphomas remains poorly understood due to the lack of CD229 monoclonal antibodies (mAb) for immunohistochemistry application (IHC). In this study, we used a new mAb against the cytoplasmic region of CD229 to study the expression of CD229 on normal tissues and B-cell malignancies, including multiple myeloma (MM), using tissue microarrays. We showed CD229 to be restricted to hematopoietic cells. It was strongly expressed in all cases of MM and in most marginal-zone lymphomas (MZL). Moderate CD229 expression was also found in chronic lymphocyte leukemia (CLL), follicular (FL), classic mantle-cell (MCL) and diffuse large B-cell lymphoma. Given the high expression on myeloma cells, we also analyzed for the presence of soluble CD229 in the sera of these patients. Serum levels of soluble CD229 (sCD229) at the time of diagnosis in MM patients could be useful as a prognostic biomarker. In conclusion, our results indicate that CD229 represents not only a useful biomarker but also an attractive therapeutic target.
| Type: | Article |
|---|---|
| Title: | CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma |
| Location: | Switzerland |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3390/cancers14092154 |
| Publisher version: | https://doi.org/10.3390/cancers14092154 |
| Language: | English |
| Additional information: | © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Oncology, leukemia, lymphoma, myeloma, B cells, CD229, Ly9, soluble receptor, SLAM FAMILY RECEPTORS, CD150 SLAM, DIFFERENTIAL EXPRESSION, MATURATION ANTIGEN, SURFACE RECEPTORS, PLASMA-CELLS, SAP, ACTIVATION, MOLECULE, DIAGNOSIS |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Pathology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10172399 |
Archive Staff Only
 |
View Item |
